Compare Cronos Group Inc (CRON) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs T Rowe Price Group Inc — how do they compare? Cronos Group Inc trades at $3.11 (market cap $1.14B), while T Rowe Price Group Inc trades at $111.26 (market cap $24.26B). The key difference: T Rowe Price Group Inc is far larger — about 21.3× Cronos Group Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | TROW | |
|---|---|---|
Market Cap | $1.14B | $24.26B |
Sector | Health | Financials |
52-Week High | $3.27 | $121.68 |
52-Week Low | $2.30 | $86.19 |
Enterprise Value | $341.13M | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.
T. Rowe Price Group (TROW) trades at $113.77, down 0.22% on the day, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a 29.26% net income margin and a P/E of 11.42, indicating potential undervaluation. Recent Q2 2026 earnings beat expectations at $2.57 per share, supported by record assets under management and higher advisory fees, though expenses and net outflows remain headwinds.
The outlook is cautiously optimistic with earnings growth and dividend stability offering upside, but risks include expense pressures and market volatility. Analyst consensus is a Hold with a $112.17 price target, near the current price, suggesting limited near-term momentum. Institutional activity shows mixed positioning, reflecting balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
